Testing MDX2004 at increasing doses in adults with advanced tumors
Official title: A Phase 1/2, Multi-Center, Open-Label Clinical Study Evaluating MDX2004 In Participants With Advanced Tumors
Run by ModeX Therapeutics, An OPKO Health Company · NCT07110584 · Data updated 2026-11-12
This will test whether different doses of the experimental drug MDX2004 are safe and can shrink tumors in adults with advanced or metastatic cancer.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 235 (estimated) |
| Sponsor | ModeX Therapeutics, An OPKO Health Company Industry-sponsored |
| Drugs / interventions | prednisone |
| Locations | 6 sites (Liverpool, New South Wales and 5 other locations) |
| Status | Recruiting |
| Started | October 1, 2025 |
| Main results expected | June 30, 2031 |
| Study ends | June 30, 2031 |
| Registry record updated | March 5, 2026 |
| Trial ID | NCT07110584 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with histologically or cytologically confirmed locally advanced or metastatic malignancy, ECOG 0–1, at least one measurable lesion, and adequate hematologic, hepatic, and renal function are candidates.
✕Probably not a fit
Patients with uncontrolled or untreated brain metastases, clinically significant cardiac disease, unresolved toxicities from prior therapy, or prior grade 3–4 immune-related toxicity leading to treatment stop are unlikely to be eligible or benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 1/2 program uses a dose-escalation phase to identify a tolerable dose of MDX2004 followed by a dose-expansion phase to gather additional safety and anti-tumor activity data. Eligible adults must have histologically confirmed locally advanced or metastatic malignancy, ECOG performance status 0–1, measurable disease per RECIST v1.1, and adequate organ function. Key exclusions include significant cardiac disease, unresolved toxicities from prior anticancer therapy, active untreated brain metastases, and prior severe immune-related toxicity that caused treatment discontinuation. Participants will receive MDX2004 and be monitored for adverse events, laboratory changes, and tumor response.
Why it matters
Potential benefit: If effective, MDX2004 could provide tumor control or clinical benefit for some patients with advanced cancers who have limited treatment options.
How similar studies have gone: Dose-escalation followed by expansion is a common approach and similar investigational anti-cancer agents have shown activity in some tumor types, but MDX2004 itself is investigational and unproven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participant must be ≥ 18 years of age. * Histologically or cytologically confirmed diagnosis of locally advanced or metastatic malignancy. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * All participants should have at least 1 measurable site of disease according to RECIST v1.1. An irradiated lesion can be considered measurable only if progression has been demonstrated on the irradiated lesion. * Adequate hematologic, hepatic and renal function. * All contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * Capable of giving signed informed consent. Exclusion Criteria: * Any clinically significant cardiac disease. * Unresolved toxicities from previous anticancer therapy. * Known untreated, active, or uncontrolled brain metastases. * Previous Grade 3 or 4 immune-related toxicity that led to the discontinuation of treatment, within 6 months prior to the first dose of MDX2004. * Active medical condition requiring chronic systemic steroid use (\>10 mg/day prednisone or equivalent) or immunosuppressive therapy, within 6 months prior to the first dose of MDX2004. * Known positivity with human immunodeficiency virus (HIV), known active hepatitis B or C, or uncontrolled chronic or ongoing infection requiring intravenous treatment. * Prior solid organ or hematologic transplant * Require supplemental oxygen for activities of daily living * Participant is not suitable for participation, whatever the reason, as judged by the Investigator including medical or clinical conditions.
Where it's running
-
Liverpool Hospital
Liverpool, New South Wales, Australia Recruiting -
Calvary Mater Newcastle
Waratah, New South Wales, Australia Recruiting -
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia Recruiting -
Rambam Health Care Campus
Haifa, Israel Recruiting -
Hadassah University Hospital-Ein Kerem
Jerusalem, Israel Recruiting -
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel Recruiting
Study contacts
- Study coordinator: ModeX Therapeutics, An OPKO Health Company
- Email: info@modextx.com
- Phone: +1 857-233-9936
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
GW01-200 tablets in people with advanced cancers
This early-phase study tests GW01-200 tablets in adults with advanced solid tumors or blood cancers to see if they are safe and how they behave in the body.
-
SIBP-A10 injection for adults with advanced malignant tumors
This trial will test whether SIBP-A10 injections are safe and tolerable and to identify the best dose for adults with advanced metastatic tumors.
-
AL58805 treatment for people with advanced solid tumors.
This Phase I dose-escalation trial will test different oral doses of AL58805 in people with advanced solid tumors who have exhausted standard treatment options.
-
Personalized neoantigen vaccine combined with radiotherapy for advanced tumors
This study is testing a personalized vaccine made from a patient's own tumor cells combined with radiotherapy to see if it can help people with advanced tumors that haven't responded to standard treatments.
-
Evaluating CS23546 for patients with advanced tumors
This study is testing a new treatment called CS23546 to see if it's safe and how well it works for people with advanced tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.